BeOne has achieved FDA approval for its treatment targeting lymphoma, marking a notable advancement in the field.
In related news, Regenxbio is positioning itself in the competitive landscape of Duchenne gene therapy.
These developments highlight the ongoing innovations and challenges within the biotech sector, as companies strive to address critical health issues.